US 12,011,425 B2
Hepatitis B antiviral agents
Yao-Ling Qiu, Andover, MA (US); Xuri Gao, Newtonville, MA (US); Jorden Kass, Arlington, MA (US); Hui Cao, Belmont, MA (US); Wei Li, Lexington, MA (US); Xiaowen Peng, Sudbury, MA (US); Byung-Chul Suh, Lexington, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by ENANTA PHARMACEUTICALS, INC., Watertown, MA (US)
Filed on Jan. 25, 2023, as Appl. No. 18/101,258.
Application 17/166,046 is a division of application No. 16/114,842, filed on Aug. 28, 2018, granted, now 10,952,978, issued on Mar. 23, 2021.
Application 18/101,258 is a continuation of application No. 17/166,046, filed on Feb. 3, 2021, granted, now 11,596,611.
Claims priority of provisional application 62/550,992, filed on Aug. 28, 2017.
Prior Publication US 2023/0241012 A1, Aug. 3, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/167 (2006.01); A61K 31/337 (2006.01); A61K 31/34 (2006.01); A61K 31/351 (2006.01); A61K 31/357 (2006.01); A61K 31/397 (2006.01); A61K 31/401 (2006.01); A61K 31/4015 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/4192 (2006.01); A61K 31/421 (2006.01); A61K 31/426 (2006.01); A61K 31/4409 (2006.01); A61K 31/4439 (2006.01); A61K 31/47 (2006.01); A61K 31/513 (2006.01); A61K 31/7028 (2006.01); A61P 31/20 (2006.01); C07C 303/00 (2006.01); C07C 317/44 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/167 (2013.01) [A61K 31/337 (2013.01); A61K 31/34 (2013.01); A61K 31/351 (2013.01); A61K 31/357 (2013.01); A61K 31/397 (2013.01); A61K 31/401 (2013.01); A61K 31/4015 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/4192 (2013.01); A61K 31/421 (2013.01); A61K 31/426 (2013.01); A61K 31/4409 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 31/513 (2013.01); A61K 31/7028 (2013.01); A61P 31/20 (2018.01); C07C 303/00 (2013.01); C07C 317/44 (2013.01); A61K 45/06 (2013.01); C07B 2200/05 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/10 (2017.05); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05); C07C 2602/44 (2017.05); C07C 2602/50 (2017.05)] 17 Claims
 
1. A pharmaceutical composition comprising a compound represented by the formula

OG Complex Work Unit Chemistry
wherein R is hydrogen or fluorine;
and a pharmaceutically acceptable carrier or excipient.